This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Features of alpha-HBDH in COVID-19 patients with different ages,outcomes and clinical types: a cohort study
Preprint
in English
| medRxiv
| ID: ppmedrxiv-20222612
ABSTRACT
BackgroundCoronavirus disease-2019 (COVID-19) has spread all over the world and brought extremely huge losses. At present, there is no study to systematically analyse the features of hydroxybutyrate dehydrogenase (-HBDH) in COVID-19 patients with different ages, clinical types and outcomes. MethodsElectronic medical records including demographics, clinical manifestation, -HBDH test results and outcomes of 131 hospitalized COVID-19 patients, with confirmed result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection, were extracted and analyzed. ResultsThe -HBDH value in [≥]61 years old group, severe group and critical group, death group all increased at first and then decreased, while no obvious changes were observed in other groups. And there were significant differences of the -HBDH value among different age groups (P<0.001), clinical type groups (P<0.001) and outcome groups (P<0.001). The optimal scale regression model showed that -HBDH value (P<0.001) and age (P<0.001) were related to clinical type. Conclusions-HBDH value increases in some COVID-19 patients, obviously in [≥]61 years old, death and critical group, indicating that patients in these three groups suffer from more serious tissues and organs damage, higher -HBDH value and risk of death. The obvious difference between death and survival group in early stage may provide a approach to judge the prognosis. The accuracy of the model to distinguish severe/critical type and other types is 85.84%, suggesting that -HBDH could judge the clinical type of COVID-19 patients accurately. In brief, -HBDH is an important indicator to judge the severity and prognosis of COVID-19.
cc_by_nc_nd
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Type of study:
Cohort_studies
/
Experimental_studies
/
Observational study
/
Prognostic study
/
Rct
Language:
English
Year:
2020
Document type:
Preprint